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Conclusions: HCV coinfection harmfully affects liver fibrosis in HBV patients, while decompensated cirrhosis is increased in coinfected patients compared with HBV-or HCV-monoinfected patients. HCV treatment is as safe and effective in coinfected as monoinfected patients and should be considered following the same rules as HCV monoinfected patients.
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| Statistical analysis
We compared characteristics at inclusion between (1) coinfected and HBV-monoinfected patients and (2) coinfected and HCV-monoinfected patients using conditional logistic regression models. Characteristics with P < .05 in bivariable models were included in multivariable models. When the characteristic was a nominal variable, the reference category was chosen as the level with the largest sample size and other categories were aggregated to the reference if they did not significantly differ from the reference in bivariable models. 6 We used multiple imputation method by chained equations to handle missing measurements. The final inference for multiple imputations was combined from 10 sets of imputed samples. Standard logistic regression model was used to ts. A P < .05 was chosen to indicate statistical significance. All analyses were performed using SAS v9.4 (SAS Inc, Cary, NC, USA).
| RESULTS
Patient characteristics are presented in Table 1 . Mean age was 55 years (range = 21-81) and 349 (41%) patients were female. The median time since HBV and/or HCV diagnosis was 14 years (interquartile range
[IQR] = 6-24) and 13 years (IQR = 7-21), respectively.
Patients' geographic origin was differently distributed between coinfected and HCV-monoinfected patients, with French geographic origin more frequent in HCV monoinfected (61%) compared to HBV/HCV coinfected patients (32%). The mode of transmission differed between coinfected and HBV-monoinfected patients (P < .0001) with a higher proportion of injecting drug use and transfusion risk categories in coinfected patients.
Severe fibrosis or cirrhosis was more frequent in coinfected patients (58%) than in HBV-monoinfected patients (32%, P < .0001), while there was no difference in the proportion of severe fibrosis or cirrhosis compared to HCV-monoinfected patients (52%, P = .3142). The proportion of decompensated cirrhosis was higher in coinfected patients (11%) than any of the two HBV and HCV-monoinfected groups (2% and 4%, respectively, P = .0275).
Past excessive alcohol use was more frequent in coinfected patients (26%) than in HBV monoinfected patients (12%, P = .0011)
while there was no difference in the proportion of past excessive alcohol use compared to HCV-monoinfected patients. The proportion classified as overweight or obese did not differ between coinfected and HBV or HCV-monoinfected patients, nor was there any difference in the proportion with diabetes. However, arterial hypertension was more frequently observed in coinfected patients (42%) than either group of monoinfected patients (HBV, 26%; P = .0026;
HCV, 25%; P = .0006).
Hepatitis B virus DNA was available at baseline for 86 coinfected and 303 HBV-monoinfected patients, with no significant difference in the proportion of detectable HBV DNA levels (>50 IU/mL) between the two groups (26% vs 35%, respectively, P = .0656).
However, a lower proportion of coinfected patients was receiving (Table 2) . Of note, the strength of association between coinfection and severe fibrosis or cirrhosis was particularly strong (adjusted-OR comparing F3/F4 vs F0/F1/F2 = 3.84, 95% CI 1.99-7.43) and independent from past excessive alcohol use. Analysis using multiple imputed data did not modify the associations.
Geographic origin and decompensated cirrhosis remained positively associated with coinfection in HCV-monoinfected patients in multivariable analysis (Table 3 ). The multivariate adjusted-OR for decompensated cirrhosis was 3.02 (95% CI 1.22-7.44). The findings were similar when using multiple imputed data or when removing HDV coinfected patients from analysis. | 1057 coinfection presented with higher prevalence of advanced fibrosis despite the lower proportion with HBV DNA replication.
| DISCUSSION
Given the similar routes of transmission, at least with respect to parenteral risk, HCV coinfection is generally reported in around 5%
of HBV-infected patients. [2] [3] [4] The varying degrees of prevalence between at-risk groups were confirmed in our study by the fact that the Asian origin was less frequent in co-infected than in HBV-monoinfected patients. 8 Our results confirm the harmful effect of HCV coinfection in HBV-infected patients, specifically in the absence of delta superinfection. [2] [3] [4] [5] [6] [7] [8] Similar to HDV super-infection in most studies, HBV/HCV coinfection would appear to accelerate liver disease progression and increase the risk of HCC. [1] [2] [3] In Hepather, we were able to describe a more thorough clinical pattern of disease severity in HBV/HCV coinfected patients of mostly European descent, yet its significance is unclear. The more frequent observation of arterial hypertension among HBV/HCV coinfected patients is an intriguing finding and was independent from age, BMI or gender. This negative factor was counterbalanced by the lack of pro-fibrotic factors. The proportion of overweight and obese patients tended to be lower in co-infected than either HBV or HCV mono-infected patients. HBV DNA replication is generally lower in co-infected patients, possibly due to the suppressive effect of HCV infection, who could then be less likely indicated for anti-HBV nucleoside/nucleotide analog therapy. This could perhaps in turn explain why significantly less co-infected patients received treatment in our study. Excessive alcohol use could also play a role in increased risk of liver morbidity, yet we did not observe differences in alcohol use at entry between co-infected and either monoinfected groups and severe fibrosis or cirrhosis as well as decompensated cirrhosis remained associated with coinfection despite adjustment on past excessive alcohol use. These findings are in line with those from the EPIB study showing that, HCV-seropositive status remained an independent risk-factor for higher stages of liver fibrosis in more than 700 HBsAg-positive patients, even after adjustment for age, male gender and daily alcohol intake >40 g. pathogenic role of both viruses. 2, 9 Considering the cross-sectional nature of our study, we were unable to clearly confirm whether HBV DNA suppression was attributed to anti-HBV therapy; nevertheless, the low level of HBV DNA replication across groups would suggest that HCV would be mainly responsible for fibrosis-associated injury.
As recommended by guidelines from the European Association for the Study of the Liver, 4 HBV-HCV coinfected patients should usually receive first-line treatment for HCV because of (1) the higher rate of decompensated cirrhosis in co-infected patients compared to HCV mono-infected patients despite a lower prevalence of HBV replication, and (2) no differences in HCV sustained virological response rates between co-infected and HCV-monoinfected patients 8, [11] [12] [13] [14] (data not shown). Co-infected patients might need closer monitoring due to the potential, albeit very rare, risk of HBVreactivation associated with HCV clearance during or after treatment, 15 as recently indicated with DAA regimens by several drug agencies. [16] [17] [18] [19] [20] HCV treatment is as safe and effective in coinfected as monoinfected patients and should be considered following the same rules as HCV-monoinfected patients.
Our study has some limitations. One was the often subjective and non-uniform way in which liver fibrosis was assessed between centres. All patients did not undergo a liver biopsy and most were evaluated on the basis of noninvasive markers of fibrosis. Misclassification could have been dually increased by the discrepancies observed between noninvasive fibrosis markers and the significant decrease of fibrosis scores linked to viral suppression. We instead asked physicians to clearly indicate their interpretation of true fibrosis levels at baseline using the measures available to them, while speculating that such an evaluation would be probably more accurate than only one noninvasive measure. We cannot exclude the possibility of referral bias that could have led to higher prevalence of decompensation in co-infected patients. Finally, the inclusion of HDV-coinfected patients may have muddled analysis in the HBV-HCV coinfected group and any conclusion regarding the possible effects of antiviral therapy on the natural history of coinfected patients. As HDV serostatus was unable to be controlled for in analysis, we cannot evaluate its confounding effect on our results.
In summary, HBV and HCV coinfection harmfully impacts liver fibrosis. Anti-HCV treatment should be considered following the same rules as HCV-monoinfected patients, especially as its efficacy is not impaired by HBV coinfection. Furthermore, treatment for HBV should be adjusted to recommendations according to viral load, underlying liver disease and risk of reactivation associated with HCV viral suppression.
